Should I buy or sell 9 Meters Biopharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares. View NMTR analyst ratings or view top-rated stocks .

What is 9 Meters Biopharma's stock price target for 2024?

1 brokerages have issued 12-month price objectives for 9 Meters Biopharma's stock. Their NMTR share price targets range from $1.70 to $1.70. On average, they predict the company's stock price to reach $1.70 in the next twelve months. View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts .

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

Shares of 9 Meters Biopharma reverse split before market open on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of 9 Meters Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST) , Miragen Therapeutics (MGEN) , Bionano Genomics (BNGO) , Evofem Biosciences (EVFM) , Outlook Therapeutics (OTLK) , Tonix Pharmaceuticals (TNXP) , Alibaba Group (BABA) , Cellectar Biosciences (CLRB) , Pfizer (PFE) and Soleno Therapeutics (SLNO) .

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NMTR

9 Meters Biopharma (NMTR) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free NMTR Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $0.00
▼
$0.02
52-Week Range: N/A

Volume: N/A
Average Volume: 315,915 shs
Market Capitalization: $1.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.70

Get 9 Meters Biopharma alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About 9 Meters Biopharma Stock (NASDAQ:NMTR)

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

NMTR Stock News Headlines

December 14, 2023 | bbc.com

Energy firms likely to miss smart meter deadline, warns Which?

November 8, 2023 | bizjournals.com

Deal reached to sell some assets of bankrupt Raleigh firm

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 7, 2023 | finance.yahoo.com

9 Meters Biopharma, Inc. (NMTRQ)

October 17, 2023 | investing.com

9 Meters Biopharma Inc (NMTRQ)

August 16, 2023 | fool.com

9 Meters Biopharma (OTC: NMTR.Q)

July 18, 2023 | bizjournals.com

Raleigh firm joins worrying trend of bankruptcies for drugmakers

July 18, 2023 | reuters.com

Drug developer 9 Meters Biopharma files for bankruptcy protection

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

July 18, 2023 | finance.yahoo.com

Why Are 9 Meters Biopharma Shares Nosediving Today?

May 30, 2023 | bizjournals.com

Temperato resigns as CEO of Raleigh drugmaker

May 30, 2023 | finance.yahoo.com

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

May 28, 2023 | fool.com

9 Meters Biopharma (NASDAQ: NMTR)

May 25, 2023 | uk.finance.yahoo.com

NMTR - 9 Meters Biopharma, Inc.

May 19, 2023 | msn.com

Citigroup Maintains 9 Meters Biopharma (NMTR) Neutral Recommendation

May 15, 2023 | finance.yahoo.com

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

April 5, 2023 | finance.yahoo.com

9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

March 30, 2023 | bizjournals.com

Why this Raleigh pharma just cut half its workforce

March 28, 2023 | finance.yahoo.com

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022

March 25, 2023 | seekingalpha.com

NMTR 9 Meters Biopharma, Inc.

March 22, 2023 | benzinga.com

9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and Forecast

March 16, 2023 | bizjournals.com

Raleigh pharma raises $5M as phase 3 study begins

March 15, 2023 | finance.yahoo.com

9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 14, 2023 | finance.yahoo.com

9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

March 7, 2023 | finance.yahoo.com

9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

February 23, 2023 | theguardian.com

Suppliers told to remove prepayment meters that were wrongly force-fitted

January 31, 2023 | finance.yahoo.com

9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference

See More Headlines

Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:NMTR
CUSIP: N/A
CIK: 1551986
Web: www.9meters.com
Phone: (919) 275-1933
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.70
High Stock Price Target: $1.70
Low Stock Price Target: $1.70
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-43,770,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -584.97%
Return on Assets: -159.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.59
Quick Ratio: 0.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 14,336,000
Free Float: 13,992,000
Market Cap: $1.04 million
Optionable: No Data
Beta: 1.36

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Ms. Bethany Sensenig C.M.A. (Age 47)
M.B.A., Interim CEO & CFO
Comp: $525.59k
Dr. Peter H. R. Green M.D.
Clinical & Scientific Advisor and Consultant
Mr. Joseph A. Murray M.D.
Clinical & Scientific Advisor and Consultant
Dr. Ciaran P. Kelly M.D.
Clinical & Scientific Advisor and Consultant
Dr. Elena Verdu M.D.
Ph.D., Clinical & Scientific Advisor and Consultant
Mr. Markku Mäki M.D.
Ph.D., Clinical & Scientific Advisor and Consultant
Dr. William J. Sandborn M.D. (Age 60)
Ph.D., Clinical & Scientific Advisor and Consultant
Dr. Roger Liddle M.D.
Clinical & Scientific Advisor and Consultant
Dr. Anthony J. Dimarino Jr.
Clinical & Scientific Advisor and Consultant
Dr. Brian Gordon Feagan FRCPC
M.D., M.P.H., Clinical & Scientific Advisor and Consultant

Key Competitors

View All Competitors

Insiders

Bethany Sensenig
Sold 9,100 shares
Total: $11,011.00 ($1.21/share)

View All Insider Transactions

NMTR Stock Analysis - Frequently Asked Questions

Should I buy or sell 9 Meters Biopharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares.
View NMTR analyst ratings or view top-rated stocks.
What is 9 Meters Biopharma's stock price target for 2024?: 1 brokerages have issued 12-month price objectives for 9 Meters Biopharma's stock. Their NMTR share price targets range from $1.70 to $1.70. On average, they predict the company's stock price to reach $1.70 in the next twelve months.
View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts.
How were 9 Meters Biopharma's earnings last quarter?: 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.26.
When did 9 Meters Biopharma's stock split?: Shares of 9 Meters Biopharma reverse split before market open on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of 9 Meters Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO).
How do I buy shares of 9 Meters Biopharma?: Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMTR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

9 Meters Biopharma (NMTR) Stock Price, News & Analysis

About 9 Meters Biopharma Stock (NASDAQ:NMTR)

NMTR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

NMTR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info